Clinical trials: Growth Disorder
Retinopathy of Prematurity
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study
In premature infants, propranolol (Prop) treatment might suppress continuing neo-vascularization (NV) and decelerate the progression of retinopathy of prematurity (ROP) towards its severe stages (III-V), thus avoiding the need of…
- Trial name
- NCT01238471
- Testing
- propranolol, sucrose 5%
- Where
- 4 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Rambam Health Care Campus
Growth Hormone Deficiency
A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency
This will be the first clinical study of the development of PHA-794428 in a pediatric population. Since differences in PK and/or PD response may occur between adult and pediatric subjects, it is deemed appropriate to first…
- Trial name
- NCT00314938
- Testing
- PHA-794428
- Where
- 7 sites in Belgium, France and 3 more
- Volunteers
- 32 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer.
- Trial name
- SQUIRE (NCT00981058)
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 182 sites in United States, Australia and 24 more
- Volunteers
- 1,093 people
- Sponsor
- Eli Lilly and Company
Preterm Labor, Maternal Psychological Distress
Fetal Brain Growth - Pilot Study
The goal of this observational prospective study is to explore the feasibility of measuring fetal and neonatal brain growth using 2D and 3D ultrasound in fetuses exposed to threatened preterm labor (TPTL) and antenatal…
- Trial name
- NCT05994443
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Premature Birth of Newborn
Comparison of Post-Discharge Growth of Premature Infants Using Two Different Formulas
The objective of this study is to compare the post-discharge growth of preterm infants fed with 2 different post discharge formulas.
- Trial name
- NCT01759134
- Testing
- Post discharge formula
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Shaare Zedek Medical Center
Unilateral Cleft Lip and Palate, Cleft Lip
Evaluation of Facial Growth in Two Primary Protocols Used in the Surgical Treatment of Unilateral Cleft Lip and Palate Patients
The purpose of this study is to evaluate which surgical protocol for treating Unilateral Cleft Lip and Palate (UCLP), a single or two stage repair ( with hard palate late closure) will have less impact in mid facial growth.
- Conditions
- Unilateral Cleft Lip and Palate, Cleft Lip, Cleft Palate, Developmental Disabilities
- Trial name
- NCT02329509
- Testing
- two stage palate surgical repair, One stage Palate Surgical repair
- Volunteers
- 64 people
- Sponsor
- Professor Fernando Figueira Integral Medicine Institute
Stunting
Characterisation and Sociodemographic Determinants of Stunting Among Malaysian Children Aged 6-19 Years
Child stunting remains an important global health issue, with 157 million children under five years of age estimated to be stunted in 2014.
- Trial name
- NCT03364426
- Testing
- No intervention
- Volunteers
- 6,759 people, healthy volunteers welcome
- Sponsor
- Manjinder Sandhu
Ovarian Neoplasms
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal…
- Trial name
- NCT00913835
- Testing
- Olaratumab, liposomal doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Prenatal Disorder, Premature Birth
Develop a Multi-disciplinary Approach for a Personalized Prenatal Diagnostics and Care for Twin Pregnancies
Different screening modalities evaluation to develop algorithms to predict pregnancy complications in twin pregnancies, and evaluation of serologic response to BNT162b2 Pfeizer/BioNTech vaccination.
- Conditions
- Prenatal Disorder, Premature Birth, Twin Pregnancy With Antenatal Problem, Twin; Pregnancy, Affecting Fetus or Newborn
- Trial name
- PRETWINSCREN (NCT04595214)
- Testing
- TTTS cases are treated by intra-uterine laser for separation.
- Where
- 7 sites in Belgium, Canada and 4 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Assaf-Harofeh Medical Center
Metabolic Syndrome
Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.
Study hypothesis: Low dose growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity and the metabolic profile of subjects with metabolic syndrome.
- Trial name
- NCT00720616
- Testing
- Norditropin
- Where
- United States
- Sponsor
- Oregon Health and Science University
Metastatic Triple Negative Breast Cancer
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib [AZD6738]) and…
- Trial name
- NCT03330847
- Testing
- Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Where
- 141 sites in United States, Belgium and 13 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Weight Loss, Weight Gain
Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight
The primary objective of this study is to determine to what extent provision with RUTF will promote catch up growth in children following an acute uncomplicated episode of P. falciparum malaria.
- Conditions
- Weight Loss, Weight Gain, Convalescence, Malaria
- Trial name
- NCT00819858
- Testing
- RUTF (Plumpynut®)
- Where
- Republic of the Congo
- Volunteers
- 180 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Growth Hormone Deficiency
National Cooperative Growth Study in CKD
The purpose of this study is to learn whether growth hormone being administered to children with Chronic Kidney Disease is effective and if it has any side effects.
- Trial name
- NCGS (NCT00616278)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis
Peripheral Nerve Injury Upper Limb
Ultrasound Guided Placental Growth Factor Vs Platelet Rich Plasma Injection in Peripheral Nerve Injury: an Interventional Study
The goal of this clinical trial is to learn if placental growth factor injection and platelet rich plasma injection works to treat peripheral nerve injury in adults.
- Trial name
- NCT06638008
- Testing
- perineural injection
- Volunteers
- 75 people
- Sponsor
- Assiut University
Periodontitis, Alveolar Bone Loss
Phase 3 Clinical Trial of Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2(Trafermin)
This study aims to verify the effectiveness of Trafermin (recombinant human basic fibroblast growth factor) in stimulating regeneration of periodontal tissue lost by periodontitis and to evaluate the safety of such stimulation.
- Conditions
- Periodontitis, Alveolar Bone Loss, Periodontal Attachment Loss
- Trial name
- NCT00734708
- Testing
- Trafermin (genetical recombination)
- Where
- 21 sites in Japan
- Volunteers
- 328 people
- Sponsor
- Kaken Pharmaceutical
Breast Cancer
HER2-low Unresectable and/or Metastatic Breast Cancer in Russia
Planned study population consists of approximately 3,150 adult patients with HER2-negative (IHC 0, + or IHC2+/ISH-) unresectable or metastatic BC enrolled to the study in order to obtain approximately 2,000 patients with…
- Trial name
- NCT05913440
- Where
- 40 sites in Russia
- Volunteers
- 1,669 people
- Sponsor
- AstraZeneca
Hypoxia, Anemia
Diastolic Deceleration Area in Early-onset FGR
DDA is a new Doppler parameter aiming to assess fetal well-being in-utero. Early-onset SGR is a specific subgroup of fetuses where the clinical application of this Doppler modality could play an important role in the detection of…
- Trial name
- NCT05820464
- Testing
- DDA Doppler
- Where
- Bulgaria
- Volunteers
- 300 people
- Sponsor
- Orthogyn Medical Center, Bulgaria
Hepatocellular Carcinoma
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
- Trial name
- NCT01733004
- Testing
- MM-141
- Where
- 4 sites in United States, France
- Volunteers
- 42 people
- Sponsor
- Merrimack Pharmaceuticals
Non Small Cell Lung Cancer
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
- Trial name
- NCT00986284
- Testing
- gefitinib
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital